Mark Lefever
Ventana Medical Systems
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mark Lefever.
Laboratory Investigation | 2017
Wenjun Zhang; Antony Hubbard; Tobin Jones; Adriana Racolta; Srabani Bhaumik; Nick Cummins; Liping Zhang; Karl Garsha; Frank Ventura; Mark Lefever; Zhenqiang Lu; John K. Hurley; William Day; Lidija Pestic-Dragovich; Larry Morrison; Lei Tang
The ability to simultaneously visualize the presence, abundance, location and functional state of many targets in cells and tissues has been described as a true next-generation approach in immunohistochemistry (IHC). A typical requirement for multiplex IHC (mIHC) is the use of different animal species for each primary (1°Ab) and secondary (2°Ab) antibody pair. Although 1°Abs from different species have been used with differently labeled species-specific 2°Abs, quite often the appropriate combination of antibodies is not available. More recently, sequential detection of multiple antigens using 1°Abs from the same species used a microwaving treatment between successive antigen detection cycles to elute previously bound 1°Ab/2°Ab complex and therefore to prevent the cross-reactivity of anti-species 2°Abs used in subsequent detection cycles. We present here a fully automated 1°Ab/2°Ab complex heat deactivation (HD) method on Ventanas BenchMark ULTRA slide stainer. This method is applied to detection using fluorophore-conjugated tyramide deposited on the tissue and takes advantage of the strong covalent bonding of the detection substrate to the tissue, preventing its elution in the HD process. The HD process was characterized for (1) effectiveness in preventing Ab cross-reactivity, (2) impact on the epitopes and (3) impact on the fluorophores. An automated 5-plex fluorescent IHC assay was further developed using the HD method and rabbit 1°Abs for CD3, CD8, CD20, CD68 and FoxP3 immune biomarkers in human tissue specimens. The fluorophores were carefully chosen and the narrow-band filters were designed to allow visualization of the staining under fluorescent microscope with minimal bleed through. The automated 5-plex fluorescent IHC assay achieved staining results comparable to the respective single-plex chromogenic IHC assays. This technology enables automated mIHC using unmodified 1°Abs from same species and the corresponding anti-species 2°Ab on a clinically established automated platform to ensure staining quality, reliability and reproducibility.
Laboratory Investigation | 2017
William Day; Mark Lefever; Robert L. Ochs; Anne Pedata; Lauren Behman; Julia Ashworth-Sharpe; Donald Johnson; Eric May; James Grille; Esteban Roberts; Jerry W Kosmeder; Larry Morrison
Multiplexed analysis of multiple biomarkers in a tissue sample requires use of reporter dyes with specific spectral properties that enable discrimination of signals. Conventional chromogens with broad absorbance spectra, widely used in immunohistochemistry (IHC), offer limited utility for multiplexed detection. Many dyes with narrow absorbance spectra, eg rhodamines, fluoresceins, and cyanines, potentially useful for multiplexed detection are well-characterized; however, generation of a chromogenic reagent useful for IHC analysis has not been demonstrated. Studies reported herein demonstrate utility of tyramine-chemistry for synthesis of a wide variety of new chromogenic dye conjugates useful for multiplexed in situ analysis using conventional light microscopes. The dyes, useful individually or in blends to generate new colors, provide signal sensitivity and dynamic range similar to conventional DAB chromogen, while enabling analysis of co-localized biomarkers. It is anticipated that this new paradigm will enable generation of a wide variety of new chromogens, useful for both research and clinical biomarker analysis that will benefit clinicians and patients.
Archive | 2007
Jerome W. Kosmeder; Mark Lefever; Donald Johnson; Michael Farrell; Zhanna Zhilina; Christopher Bieniarz
Archive | 2011
Rui Hong; Hong Wang; Mark Lefever; Jan Froehlich; Christopher Bieniarz; Brian D. Kelly; Phillip Miller
Archive | 2011
Adrian E. Murillo; Jerome W. Kosmeder; Eric May; William Day; Mark Lefever; Anne Pedata; Christopher Bieniarz; Phillip Miller
Archive | 2004
Christopher Bieniarz; Michael Farrell; Jerome W. Kosmeder; Mark Lefever
Archive | 2013
Nelson Alexander; William Day; Jerome W. Kosmeder; Mark Lefever; Larry Morrison; Anne Pedata; Stacey Stanislaw
Bioconjugate Chemistry | 2010
Mark Lefever; Jerome W. Kosmeder; Michael Farrell; Christopher Bieniarz
Archive | 2006
Christopher Bieniarz; Jennifer Wong; Mark Lefever; Jerome W. Kosmeder; Julia Ashworth-Sharpe; Casey A. Kernag
Cancer Research | 2018
Esteban Roberts; William Day; Brian D. Kelly; Nathan W. Polaske; Julia Ashworth-Sharpe; Donald E. Johnson; Mark Lefever; Jerry W Kosmeder; Hongjun Zhang; Jian Zhang; Tsu-Shuen Tsao; Michael Farrell; Joerg Bredno; Robert L. Ochs; Larry E. Morrison